See how these assays offer an in-depth approach to non-invasively probe systemic health and enable decentralized clinical trials.
Sapient will be presenting on multi-omics data integration & our impact in research advancements. See where you can meet us.
This paper, published in Diabetes Care, identifies key metabolites associated with incident type 2 diabetes (T2D).
Explore advancements finally allowing drug developers to extract maximal biological insight from the plasma proteome.
This panel provides precise quantitative measurements of >150 key biomarkers of inflammation and immune response.
Sapient will be presenting on multi-omics approaches to accelerate drug discovery & development. See where to meet us.
See how our mass spectrometry-based workflows measure 3,600+ protein groups in CSF to probe the landscape of CNS disease.
Experts share best practices for leveraging multi-omics technologies and data to advance clinical research.
This multi-omics study, led by UPitt researchers, establishes causative linkages between key metabolites & PAH.
This paper, published in Science, establishes a genetic & metabolic paradigm linking key metabolites to PAH.
See how our label-free, DIA proteomics workflows measure 5,438 total protein groups, comprising ~70K peptides, in plasma.
See how the partnership complements Sapient’s mass spectrometry-based proteomics & multi-omics services.
This panel profiles 250+ biomarkers of inflammation & immune response, including low-abundance cytokines and chemokines.
This panel detects 120+ biomarkers of neurodegeneration, including neuro-specific & neuroinflammatory proteins.
How next-gen mass spectrometry provides sensitivity & specificity over the current gold standard in clinical protein assays, ELISA.
See how we deliver bespoke services for metabolomics, lipidomics, and proteomics data generation and analysis.
See how our methods enable deep coverage of the blood & tissue proteome, and are scalable to your throughput needs.
See how we capture >15K small molecule biomarkers per biosample in a single run, across thousands of samples.
Dr. Jonathan Usuka appointed Chief Executive Officer as Founder Dr. Mohit Jain transitions to Chief Scientific Officer.
Using mass spectrometry to deliver quantitative measures for specific proteins in plasma, cells, and tissue.
See how Sapient enables focused biomarker discovery analyses with rapid time-to-insight.
The Foundation's Impact Report highlights breakthroughs in our collaboration on the first diagnostic for persistent Lyme.
Sapient joins experts from Boehringer Ingelheim, ASU, The Institute of Cancer Research, London, & SciLifeLab to discuss.
Our comprehensive Metabolite Standards Library enhances the speed, quality, and extent of metabolite identification.
See how this database of data from 100,000+ biosamples enables rapid biomarker discovery & cross-validation.
From Oxford Global's Multi-Omics Symposium, sharing examples of proteomics & metabolomics applied in drug discovery.
Biocom California spotlights how Sapient is making waves in drug development through dynamic biomarker discovery.
See how how the collaboration will enable accelerated delivery of multidimensional insights to inform drug development.
Explore our semi-targeted LC-MS/MS method optimized specifically for analysis and discovery of bioactive metabolites.
Approaches to address the complexities of metabolite profiling & maximize Tier 1 identification of small molecule biomarkers.
The article asks 5 experts, including Sapient's CBO, their views on the current and future state of radioligand therapy development.
Explore how discovery proteomics combined with AI-based target validation can be used to match therapies to optimal targets.
A conversation on the future of biomarker discovery and mass spectrometry & what it means to go 'beyond the genome'.
Describing the comprehensive, systematic quality matrix for QC in Sapient’s nontargeted mass spectrometry workflows.
How proteomics & metabolomics data gives biological and patient context to advance every phase of drug development.
The paper details an innovative approach for assaying metabolic activities in intact human liver tissue.
This paper, published in Nature Metabolism, details a study making significant strides in the understanding human liver metabolism.
Deep dive into the latest advances for gathering, integrating, and leveraging multiomics data for biomarker discovery.
See how these capabilities enhance the speed, quality & extent of metabolite identification for accelerated insights.
How next-gen proteomics methods for protein biomarker discovery are opening exciting new avenues in CDx development.
Now available on demand! See the scientific innovations expanding the druggable space and enabling discovery of novel targets.
The report showcases exponential technologies in biotechnology likely to change the way our world works and lives.
Talking multiomics data and how it can take pharmacogenomics to the next level such as in predicting patient response.
Featuring Sapient's platform as an omics technology advancing the discovery & implementation of dynamic biomarkers.
How multi-omics biomarker strategies are helping to realize the incredible therapeutic potential in these pipelines today.
Dr. Usuka will lead global business strategy for commercial collaborations, strategic partnerships & client service innovations.
Using metabolite biomarkers to speed GLP-1 agonist time-to-market & drive competitive advantages via novel insights.
Explore how our /Deep/ Cell Surface Proteomics method is optimized to accelerate development of T cell engagers.
See how our method is optimized to measure cancer cell surface receptors at unprecedented depth and scale.
PharmaShots profiles Sapient's high throughput proteomics and how our services fulfill market gaps for drug development.
See how our method is optimized to evaluate degrader specificity & to screen thousands of degrader molecules for target efficiency.
Discussing how next-gen multiomics is enabling drug development transformation in the post-COVID era.
How Sapient's /Deep/ Discovery can be used to identify & target TAAs that are differentially expressed on tumors.
How biomarkers discovered via nontargeted approaches can elucidate unknown disease biology to guide therapeutic development.
Now available on demand! See how high throughput discovery proteomics achieves high analytical specificity at scale.
High confidence protein IDs. Measure of PTMs. See how our method is optimized for revealing biological insights.
Examples of how multi-omics research has “moved the needle” in expanding our understanding of complex diseases.
Discussing questions such as, what can your zip code tell us about your health that your genetic code cannot?
These services enable measure of thousands of proteins in blood and tissue across diverse biological pathways.
How discovery mass spectrometry can be used to identify biomarkers to analyze, monitor & optimize bioprocessing workflows.
Dr. Nguyen joins Bruker's Kate Stumpo for a wide-ranging conversation on her experiences in the field of omics.
Sapient's Dr. Mo Jain discusses the role next-generation mass spectrometry will play in the evolution of precision drug development.
Population health studies finally have an efficient, scalable approach to ‘go beyond the genome’ in biomarker discovery.
Dr. Jain shares how nontargeted biomarker discovery provides a nontraditional path to advance drug development.
Why data transparency is imperative to ensure the accuracy and reproducibility of findings that inform drug development.
How small molecule biomarkers can help decipher autoimmune disease dynamics and inform drug development strategies.
These ready-to-order panels speed time-to-insight through targeted exploration of known molecules.
A discussion at the intersection of high throughput biomarker profiling, advanced data analytics, and biological insight.
Now available on demand! Explore how small molecule biomarkers can drive greater understanding of autoimmune diseases.
Explore how dynamic biomarkers of target engagement and PD can help decipher the heterogeneity of ADCs and their targets.
This case study details the discovery of a biomarker of biological processes in patients with sequence-verified mitochondrial disease.
Now available on demand! Explore the applications for small molecule biomarkers in cell & gene therapy development.
“Out of graduate school, Dr. Mohit Jain (co-founder and CEO of Sapient, but a university professor at the time) approached…
“I would argue that for nearly every common disease, there are multiple forms of the disease that have been amalgamated…
The inherent heterogeneity in patient populations can often lead to variable drug response. We recently worked with a client who…
Learn how we perform discovery screenings and then can translate key identified biomarkers into clinical assays.
August 2, 2023—San Diego, CA—Sapient, a biomarker discovery organization providing bespoke services for metabolomics and lipidomics data generation and analysis,…
The PD-1 pathway has transformed the development of immunotherapies as a means to reawaken the immune system to target cancer…
Watch the Livestream Recording | Presented by Bruker Watch the full recording of our recent lab tour showing how Sapient’s next-generation, ultra-high…
Now On Demand | Hosted by Nature Research Watch Now Human disease is a highly dynamic process. While next-generation genomic sequencing has…
The incidence and prevalence of nonalcoholic fatty liver disease (NAFLD) continue to rise worldwide, estimated to affect over one-quarter of…
“Diagnostics have evolved tremendously. You could argue that the greatest benefit in human survival has come over the last 50…
Preclinical safety assessments play a pivotal role in mitigating risk to enhance drug development success. Early identification of toxicological effects…
“My hope is that in the very near future, in the next decade, an individual would go to a doctor’s…
Biocom California recently asked Sapient to contribute an article for its Lifelines Magazine, a forum sharing insights and innovations that are leading…
Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those…
Adaptive clinical trial designs are an emerging approach that bring flexibility to traditional linear study designs by adding a “review,…
Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those…
Now On Demand | Hosted by Oxford Global Advances in mass spectrometry resolution and sensitivity have enabled increasingly comprehensive views into the…
Now On Demand | Hosted by AAPS Small molecule biomarkers represent dynamic indicators of adverse effects in the setting of drug exposure…
There is increasing evidence of the human gut microbiome’s link to health and disease. Exploring the composition and function of…
If you look at the data, the best drugs work in only 50% of people. Sapient’s Founder and CEO, Dr. Mo…
Adaptive clinical trial designs seek to add flexibility to the fixed, linear “design-conduct-analyze” sequence of conventional clinic trials. Instead of assessing…
Technology Networks’ Anna MacDonald sat down with Sapient’s Dr. Mo Jain for this Industry Insights piece to discuss the importance of improving biomarker…
Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those…
Biocompare recently spoke to a panel of experts, including Sapient’s CEO and Founder, Dr. Mo Jain, to get their takes…
Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those…
Now On Demand | Hosted by AAPS Will a patient respond or not respond to the given therapy? That is the fundamental…
Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those…
Understanding the risk factors that give rise to human disease is essential to early detection and development of effective treatments…
Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those…
There are tens of thousands of unknown molecules circulating in human blood – thousands of which could represent robust biomarkers.…
Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those…
Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those…
CNS diseases can have a wide range of symptoms which can make them difficult to diagnose and treat based on…
Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those…
Sapient leverages its next-generation mass spectrometry approaches to probe deeper into the human lipidome at a rate that is unmatched…
Now On Demand | Hosted by Fierce Pharma Watch Now In this session, Sapient discusses application of its next-generation mass…
Disease processes are complex. Individuals with the same genetic disorder, symptoms, and/or diagnosis can have varied prognosis and response to…
Speed, Scale, Specificity: How Next-Generation Mass Spectrometry is Transforming Small Molecule Biomarker Profiling Now On Demand | Presented by Technology…
Dr. Jain also shares his background and what led to him to creating Sapient along with the company’s own next-generation…
Now On Demand | Hosted by AAPS Watch Now While next-generation sequencing has been instrumental in advancing genomics-based precision medicine,…
Sapient recently contributed a piece to Fierce Pharma discussing the new biological and disease insights that small molecule biomarkers can…
September 1, 2022—San Diego, CA—A study led by researchers at the University of Oxford, UK has been published in Lancet Diabetes…
Study infrastructure and biospecimen processing support is being provided by Sapient for the study, which is focused on advancing vital…
Now On Demand | Hosted by AAPS Watch Now Genome-wide association studies (GWAS) have been transformative in elucidating the genetic…
The grant from Bill & Melinda Gates Foundation will support studies to identify biomarkers that can inform novel nutritional, disease-prevention,…
An individual’s phenotype is not dictated solely by their genetic variants. Environmental factors – where we live, what we eat,…
“Sapient’s proprietary, next-generation rapid LC-MS (rLC-MS) technologies leverage the unique bioanalytical capabilities of the Bruker timsTOF Pro 2 system and enable nontargeted capture and…
Untargeted biomarker discovery aims to uncover previously unknown factors that associate with biologically relevant changes in human health and disease,…
Now On Demand | Hosted by AAPS Watch Now A key aspect of the drug discovery pipeline is evaluation of in…
Retrospective analyses conducted by major pharmaceutical companies on their drug pipelines have revealed that close to one-fifth of Phase II failures due…
A drug candidate with an associated biomarker is 2−10x more likely to obtain FDA approval. Why? Because biomarkers help to…
Now On Demand | Hosted by AAPS Watch Now Diseases are singularly defined but often represent varied groupings of contributing factors…
Learn about RExMap and our methods to advance biomarker-based discovery of microbially derived metabolites.
San Diego, CA—Sapient, a biomarker discovery organization transforming drug development through rapid, large-scale biomarker profiling, has joined the Foundation for…
High throughput technologies can now capture and measure a huge number of biological molecules within a single human cell or…
Immunotherapy has transformed the treatment of solid organ cancers, rapidly becoming a first line therapy with transformative durable response. While…
Sapient leverages its next-generation mass spectrometry approaches to probe deeper into the human metabolome at a rate is unmatched for…
San Diego, CA—Sapient, a full-service bioanalytical organization transforming drug development through biomarker discovery, has been featured in the Bay Area…
At Sapient, we believe biomarker-driven drug development can transform lives – and accelerate the process at a fraction of the…
Why are large, expensive clinical trials so common? It stems from the challenge of needing to demonstrate treatment efficacy in…
Now On Demand | Hosted by AAPS Circulating biomarker discovery is a critical component of the drug discovery process, identifying markers…
The omics revolution has enabled many breakthroughs in our understanding of disease biology, but the productivity of clinical drug development…
Nontargeted LC-MS can assay thousands of chemical entities in a single biospecimen, but in that crush of data, how do…
10421 Wateridge Circle, Suite 100
San Diego, CA 92121
discover@sapient.bio
858.290.7010
